Transcatheter mitral valve repair in patients with pulmonary hypertension


  • Mary Corcoran
  • Univadis Medical News
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

A new study published in JAMA Cardiology suggests pulmonary hypertension (pHTN) is associated with increased mortality and readmission for heart failure in patients undergoing transcatheter mitral valve repair (TMVR). 

The retrospective cohort study analysed data from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy registry for 4,071 patients who underwent TMVR with the MitraClip system between November 4, 2013, and March 31, 2017. 

Patients were stratified into four groups based on invasive mean pulmonary arterial pressure (mPAP): no pHTN (mPAP 

One-year outcomes were assessed for 2,381 patients.

The composite rate of one-year mortality and readmissions for heart failure was 33.6 per cent, and the authors reported that this was higher in those with pHTN. The rate increased from 27.8 per cent in group 1 to 32.4 per cent in group 2, 36.0 per cent in group 3 and 45.2 per cent in group 4 (P<.001>